Nateglinide and acarbose are comparably effective reducers of postprandial glycemic excursions in chinese antihyperglycemic agent-naive subjects with type 2 diabetes

Diabetes Technology and Therapeutics

Volumn 15, Issue 6, 2013, Pages 481-488

  Zhou, Jian ^a   Li, Hong ^b   Zhang, Xiuzhen ^c   Peng, Yongde ^d   Mo, Yifei ^a   Bao, Yuqian ^a   Jia, Weiping ^a  

^a SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c TONGJI HOSPITAL OF TONGJI UNIVERSITY   (China)

^d SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ALBUMIN; GLUCOSE; HEMOGLOBIN A1C; INSULIN; NATEGLINIDE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD GLUCOSE MONITORING; CHINA; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

ACARBOSE; ADOLESCENT; ADULT; ANTIHYPERTENSIVE AGENTS; AREA UNDER CURVE; BLOOD GLUCOSE; CHINA; CYCLOHEXANES; DIABETES MELLITUS, TYPE 2; FEMALE; GLYCEMIC INDEX; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PHENYLALANINE; POSTPRANDIAL PERIOD; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84878540691     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2013.0046     Document Type: Article

References (28)

1. Hirsch IB: Glycemic variability: it's not just about A1C anymore! Diabetes Technol Ther 2005;7:780-783. (Pubitemid 41572082)
2. DECODE Study Group, the European Diabetes Epidemiology Group: Glucose tolerance and cardiovascul mortality: comparison of fasting and 2-hourdagnostic criteria. Arch Intern Med 2001;161:397-405.
3. Nakagami T, Qiao Q, Tuomilehto J, Balkau B, Tajima N, Hu G, Borch-Johnsen K: Screen-detected diabetes, hypertension and hypercholesterolemia as predictors of cardiovascular mortality in five populations of Asian origin: the DECODA study. Eur J Cardiovasc Prev Rehabil 2006;13:555-561. (Pubitemid 44162157)
4. Hanefeld M, Koehler C, Schaper F, Fuecker K, Henkel E, Temelkova-Kurktschiev T: Postprandial plasma glucose is an independent risk factor for increased carotid intimamedia thickness in non-diabetic individuals. Atherosclerosis 1999;144:229-235. (Pubitemid 29259984)
5. Kawano H, Motoyama T, Hirashima O, Hirai N, Miyao Y, Sakamoto T, Kugiyama K, Ogawa H, Yasue H: Hyperglycemia rapidly suppresses flow-mediated endotheliumdependent vasodilation of brachial artery. J Am Coll Cardiol 1999;34:146-154.
6. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, Colette C: Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006;295:1681-1687.
7. Ceriello A: The glucose triad and its role in comprehensive glycaemic control: current status, future management. Int J Clin Pract 2010;64:1705-1711.
8. Praet SF, Manders RJ, Meex RC, Lieverse AG, Stehouwer CD, Kuipers H, Keizer HA, van Loon LJ: Glycaemic instability is an underestimated problem in Type II diabetes. Clin Sci (Lond) 2006;111:119-126. (Pubitemid 44220525)
9. Maia FF, Araujo LR: Efficacy of continuous glucose monitoring system (CGMS) to detect postprandial hyperglycemia and unrecognized hypoglycemia in type 1 diabetic patients. Diabetes Res Clin Pract 2007;75:30-34. (Pubitemid 44856023)
10. Wang JS, Lin SD, Lee WJ, Su SL, Lee IT, Tu ST, Tseng YH, Lin SY, Sheu WH: Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison. Clin Ther 2011;33:1932-1942.
11. Gerich J, Raskin P, Jean-Louis L, Purkayastha D, Baron MA: PRESERVE-beta: two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care 2005;28:2093-2099. (Pubitemid 41242450)
12. NAVIGATOR Study Group, Holman RR, Haffner SM, McMurray JJ, Bethel MA, Holzhauer B, Hua TA, Belenkov Y, Boolell M, Buse JB, Buckley BM, Chacra AR, Chiang FT, Charbonnel B, Chow CC, Davies MJ, Deedwania P, Diem P, Einhorn D, Fonseca V, Fulcher GR, Gaciong Z, Gaztambide S, Giles T, Horton E, Ilkova H, Jenssen T, Kahn SE, Krum H, Laakso M, Leiter LA, Levitt NS, Mareev V, Martinez F, Masson C, Mazzone T, Meaney E, Nesto R, Pan C, Prager R, Raptis SA, Rutten GE, Sandstroem H, Schaper F, Scheen A, Schmitz O, Sinay I, Soska V, Stender S, Tama's G, Tognoni G, Tuomilehto J, Villamil AS, Voza'r J, Califf RM: Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 2010;362:1463-1476.
13. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-853.
14. Monnier L: Is postprandial glucose a neglected cardiovascular risk factor in type 2 diabetes? Eur J Clin Invest 2000;30(Suppl 2):3-11. (Pubitemid 30604060)
15. Zhou J, Jia WP, Yu M, Ma XJ, Bao YQ, Lu W: The features of postprandial glucose state in type 2 diabetes mellitus [in Chinese]. Zhonghua Yi Xue Za Zhi 2006;86:970-975. (Pubitemid 43950835)
16. Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, Shan Z, Liu J, Tian H, Ji Q, Zhu D, Ge J, Lin L, Chen L, Guo X, Zhao Z, Li Q, Zhou Z, Shan G, He J; China National Diabetes and Metabolic Disorders Study Group: Prevalence of diabetes among men and women in China. N Engl J Med 2010;362:1090-1101.
17. Bao Y, Ma X, Li H, Zhou M, Hu C, Wu H, Tang J, Hou X, Xiang K, Jia W: Glycated haemoglobin A1c for diagnosing diabetes in Chinese population: cross sectional epidemiological survey. BMJ 2010;340:c2249.
18. Abrahamian H, Francesconi M, Loiskandl A, Dzien A, Prager R, Weitgasser R: Evaluation of a new insulinotropic agent by using an innovative technology: efficacy and safety of nateglinide determined by continuous glucose monitoring. Diabetes Technol Ther 2004;6:31-37. (Pubitemid 38233743)
19. Bao YQ, Zhou J, Zhou M, Cheng YJ, Lu W, Pan XP, Tang JL, Lu HJ, Jia WP: Glipizide controlled-release tablets, with or without acarbose, improve glycaemic variability in newly diagnosed Type 2 diabetes. Clin Exp Pharmacol Physiol 2010;37:564-568.
20. Kim MK, Suk JH, Kwon MJ, Chung HS, Yoon CS, Jun HJ, Ko JH, Kim TK, Lee SH, Oh MK, Rhee BD, Park JH: Nateglinide and acarbose for postprandial glucose control after optimizing fasting glucose with insulin glargine in patients with type 2 diabetes. Diabetes Res Clin Pract 2011;92:322-328.
21. Pratley RE, Weyer C: The role of impaired early insulin secretion in the pathogenesis of Type II diabetes mellitus. Diabetologia 2001;44:929-945. (Pubitemid 32778125)
22. Hollingdal M, Juhl CB, Pincus SM, Sturis J, Veldhuis JD, Polonsky KS, Porksen N, Schmitz O: Failure of physiological plasma glucose excursions to entrain high-frequency pulsatile insulin secretion in type 2 diabetes. Diabetes 2000;49: 1334-1340. (Pubitemid 30624234)
23. Polonsky KS, Given BD, Hirsch LJ, Tillil H, Shapiro ET, Beebe C, Frank BH, Galloway JA, Van Cauter E: Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med 1988;318:1231-1239.
24. Weyer C, Bogardus C, Mott DM, Pratley RE: The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999;104:787-794. (Pubitemid 29536364)
25. Haffner SM, Bowsher RR, Mykkanen L, Hazuda HP, Mitchell BD, Valdez RA, Gingerich R, Monterossa A, Stern MP: Proinsulin and specific insulin concentration in highand low-risk populations for NIDDM. Diabetes 1994;43: 1490-1493.
26. Li J, Tian H, Li Q, Wang N, Wu T, Liu Y, Ni Z, Yu H, Liang J, Luo R, Li Y, Huang L: Improvement of insulin sensitivity and beta-cell function by nateglinide and repaglinide in type 2 diabetic patients - a randomized controlled double-blind and double-dummy multicentre clinical trial. Diabetes Obes Metab 2007;9:558-565. (Pubitemid 47018519)
27. Hazama Y, Matsuhisa M, Ohtoshi K, Gorogawa S, Kato K, Kawamori D, Yoshiuchi K, Nakamura Y, Shiraiwa T, Kaneto H, Yamasaki Y, Hori M: Beneficial effects of nateglinide on insulin resistance in type 2 diabetes. Diabetes Res Clin Pract 2006;71:251-255.
28. Rudovich N, Mohlig M, Otto B, Pivovarova O, Spranger J, Weickert MO, Pfeiffer AF: Effect of meglitinides on postprandial ghrelin secretion pattern in type 2 diabetes mellitus. Diabetes Technol Ther 2010;12:57-64.